[Increase of fibrinolytic activity and reduction of platelet adhesiveness caused by prolonged treatment with ethyl-chloro-phenoxy-isobutyrate].
D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects*; D002087:Butyrates / Q000627:therapeutic use*; D005260:Female; D005341:Fibrinolysin / Q000032:analysis*; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis*
D000924:Anticholesteremic Agents; D002087:Butyrates; D008055:Lipids; D010958:Plasminogen; D005341:Fibrinolysin
Aumento dell'attività fibrinolitica e riduzione dell'adesività piastrinica da trattamento prolungato con etil-cloro-fenossi-isobutirrato.